The Centers for Medicare & Medicaid Services yesterday released a request for applications from Medicare-enrolled ambulance suppliers and providers to participate in its new payment model for emergency ambulance services beginning in 2020. Announced in February, the Emergency Triage, Treat and Transport (ET3) model will enable participating ambulance suppliers and providers to partner with qualified health care practitioners to deliver treatment in place (either on-the-scene or through telehealth) and with alternative destination sites (such as primary care doctors’ offices or urgent-care clinics) to provide care for Medicare beneficiaries following a medical emergency for which they have accessed 911 services. The five-year model also will encourage development of medical triage lines for low-acuity 911 calls in regions where participating ambulance suppliers and providers operate. CMS expects to release a notice of funding opportunity for the triage lines after selecting model participants this fall. For more on the model, see the agency’s answers to Frequently Asked Questions.
 

Related News Articles

Headline
The AHA June 4 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee in defense of the state’s 340B contract pharmacy law…
Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The AHA May 1 expressed concerns to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare Drug…